Lyme borreliosis (LB) is the most common vector-borne infectious disease in Slovenia. From 3,000 to over 6,000 patients with LB were registered annually in the period 2005–2014 in Slovenia. Since the introduction of legally required registration of LB, the incidence rate has been increasing and is one of the highest in the EU. The increase reflects better recognition of the disease, awareness of the general population about symptoms and signs consistent with LB. We assume that lifestyle, i.e. living or working in the environment where there is a possibility of infection, is equally, if not more, important than the density of ticks and environmental factors.
This indicator presents the number of reported LB cases (ICD-10 diagnoses: A69.2, G01.0, G63.0, M01.2).
Lyme borreliosis (LB) is the most common vector-borne infectious disease in Slovenia. Climate change and temperature increase, in particular, has been attributed to having a considerable impact on the changing epidemiology of vector-borne (and other) infectious diseases.
Lyme borreliosis is the second most important disease transmitted by ticks. As opposed to tick-borne meningoencephalitis, no vaccination against borreliosis exists for the time being. Lyme borreliosis is treated by antibiotics. The range of borreliosis is not limited to the areas known to be infected with tick-borne meningoencephalitis. Ticks throughout Slovenia are infected with the Lyme borreliosis agent.
Usually there are three phases in the progression of the disease. It begins with a typical rash from 3 to 32 days after the initial bite that gradually spreads outward from the place of the bite. The rash typically pales in the centre. Usually there is only one rash, but there may be several on different parts of the body. The rash may disappear without treatment, but the infection continues. In the second and third phase (possibly several months or years after the initial infection) many organs or organ systems may be affected – skin, nervous system, joints, muscles and sometimes also the eyes and heart.
National Institute of Public Health, 2006-2015
|reported cases||number of reported cases||3995||4364||3773||5092||6220||4917||5552||4943||6938||3890|
National Institute of Public Health of RS, 2006-2015
|0-4||5 - 9||10 - 14||15-19||20-24||25-29||30-34||35-39||40-44||45-49|
|Men||Incidence rate/100.000 inh.||261.1||348.1||182.1||119.5||131||137.8||160.6||186.4||224.5||250.6|
|Women||Incidence rate/100.000 inh.||251.1||294.3||140.1||115||109.7||128.4||155.8||189.2||263.4||334|
|50-54||55-59||60-64||65-69||70-74||75-79||80-84||85+||Starost - SKUPAJ|
|Men||Incidence rate/100.000 inh.||268.6||290.7||308.1||275.7||238.8||177.9||113.9||76.2||217.2|
|Women||Incidence rate/100.000 inh.||422.1||508||503.7||452.9||319.7||205.6||109.2||42||266.9|